FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200016408> ?p ?o ?g. }

• W4200016408 endingPage "7351" @default.
• W4200016408 startingPage "7351" @default.
• W4200016408 abstract "The accumulation of the various products of alpha-synuclein aggregation has been associated with the etiology and pathogenesis of several neurodegenerative conditions, including both familial and sporadic forms of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). It is now well established that the aggregation and spread of alpha-synuclein aggregation pathology activate numerous pathogenic mechanisms that contribute to neurodegeneration and, ultimately, to disease progression. Therefore, the development of a safe and effective disease-modifying therapy that limits or prevents the accumulation of the toxic intermediate products of alpha-synuclein aggregation and the spread of alpha-synuclein aggregation pathology could provide significant positive clinical outcomes in PD/DLB cohorts. It has been suggested that this goal can be achieved by reducing the intracellular and/or extracellular levels of monomeric and already aggregated alpha-synuclein. The principal aim of this review is to critically evaluate the potential of therapeutic strategies that target the post-transcriptional steps of alpha-synuclein production and immunotherapy-based approaches to alpha-synuclein degradation in PD/DLB patients. Strategies aimed at the downregulation of alpha-synuclein production are at an early preclinical stage of drug development and, although they have shown promise in animal models of alpha-synuclein aggregation, many limitations need to be resolved before in-human clinical trials can be seriously considered. In contrast, many strategies aimed at the degradation of alpha-synuclein using immunotherapeutic approaches are at a more advanced stage of development, with some in-human Phase II clinical trials currently in progress. Translational barriers for both strategies include the limitations of alpha-synuclein aggregation models, poor understanding of the therapeutic window for the alpha-synuclein knockdown, and variability in alpha-synuclein pathology across patient cohorts. Overcoming such barriers should be the main focus of further studies. However, it is already clear that these strategies do have the potential to achieve a disease-modifying effect in PD and DLB." @default.
• W4200016408 created "2021-12-31" @default.
• W4200016408 creator A5001684239 @default.
• W4200016408 creator A5026042960 @default.
• W4200016408 creator A5083584353 @default.
• W4200016408 date "2021-12-03" @default.
• W4200016408 modified "2023-09-25" @default.
• W4200016408 title "Toward a Disease-Modifying Therapy of Alpha-Synucleinopathies: New Molecules and New Approaches Came into the Limelight" @default.
• W4200016408 cites W1480945180 @default.
• W4200016408 cites W1508926134 @default.
• W4200016408 cites W1564387586 @default.
• W4200016408 cites W1721689174 @default.
• W4200016408 cites W1733944139 @default.
• W4200016408 cites W1786270771 @default.
• W4200016408 cites W1918258073 @default.
• W4200016408 cites W1964191200 @default.
• W4200016408 cites W1965095016 @default.
• W4200016408 cites W1968251608 @default.
• W4200016408 cites W1969994843 @default.
• W4200016408 cites W1971599063 @default.
• W4200016408 cites W1973649320 @default.
• W4200016408 cites W1978497589 @default.
• W4200016408 cites W1983273019 @default.
• W4200016408 cites W1989149919 @default.
• W4200016408 cites W1990473626 @default.
• W4200016408 cites W1991604513 @default.
• W4200016408 cites W2003172650 @default.
• W4200016408 cites W2011473770 @default.
• W4200016408 cites W2016398561 @default.
• W4200016408 cites W2017841165 @default.
• W4200016408 cites W2020796799 @default.
• W4200016408 cites W2029319167 @default.
• W4200016408 cites W2051098162 @default.
• W4200016408 cites W2054790952 @default.
• W4200016408 cites W2056304503 @default.
• W4200016408 cites W2057242636 @default.
• W4200016408 cites W2057358353 @default.
• W4200016408 cites W2073449985 @default.
• W4200016408 cites W2076844276 @default.
• W4200016408 cites W2078347978 @default.
• W4200016408 cites W2078955175 @default.
• W4200016408 cites W2080566347 @default.
• W4200016408 cites W2083111107 @default.
• W4200016408 cites W2095442135 @default.
• W4200016408 cites W2098069894 @default.
• W4200016408 cites W2115298392 @default.
• W4200016408 cites W2122688529 @default.
• W4200016408 cites W2131222480 @default.
• W4200016408 cites W2156806006 @default.
• W4200016408 cites W2158089391 @default.
• W4200016408 cites W2164627569 @default.
• W4200016408 cites W2178750505 @default.
• W4200016408 cites W2271618092 @default.
• W4200016408 cites W2295603197 @default.
• W4200016408 cites W2417395660 @default.
• W4200016408 cites W2471760960 @default.
• W4200016408 cites W2486383000 @default.
• W4200016408 cites W2557770353 @default.
• W4200016408 cites W2577340531 @default.
• W4200016408 cites W2591620984 @default.
• W4200016408 cites W2605895028 @default.
• W4200016408 cites W2610501046 @default.
• W4200016408 cites W2620755219 @default.
• W4200016408 cites W2734347586 @default.
• W4200016408 cites W2738605841 @default.
• W4200016408 cites W2752380554 @default.
• W4200016408 cites W2757999655 @default.
• W4200016408 cites W2763748630 @default.
• W4200016408 cites W2769601563 @default.
• W4200016408 cites W2778992055 @default.
• W4200016408 cites W2801299411 @default.
• W4200016408 cites W2890071927 @default.
• W4200016408 cites W2892946876 @default.
• W4200016408 cites W2898588982 @default.
• W4200016408 cites W2899245410 @default.
• W4200016408 cites W2909713798 @default.
• W4200016408 cites W2918616772 @default.
• W4200016408 cites W2920438880 @default.
• W4200016408 cites W2946411003 @default.
• W4200016408 cites W2950512452 @default.
• W4200016408 cites W2953518553 @default.
• W4200016408 cites W2953534538 @default.
• W4200016408 cites W2961720330 @default.
• W4200016408 cites W2969666786 @default.
• W4200016408 cites W2979100606 @default.
• W4200016408 cites W3003167876 @default.
• W4200016408 cites W3011843994 @default.
• W4200016408 cites W3036340459 @default.
• W4200016408 cites W3043410331 @default.
• W4200016408 cites W3088641381 @default.
• W4200016408 cites W3118586567 @default.
• W4200016408 cites W3133927909 @default.
• W4200016408 cites W3136755667 @default.
• W4200016408 cites W3139357521 @default.
• W4200016408 cites W3176522352 @default.
• W4200016408 cites W3205974737 @default.
• W4200016408 cites W3210387586 @default.
• W4200016408 cites W4210584483 @default.

• next